(NASDAQ: NKTX) Nkarta's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.88%.
Nkarta's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast NKTX's revenue for 2027 to be $585,720,658, with the lowest NKTX revenue forecast at $585,720,658, and the highest NKTX revenue forecast at $585,720,658. On average, 3 Wall Street analysts forecast NKTX's revenue for 2028 to be $5,900,465,228, with the lowest NKTX revenue forecast at $779,079,044, and the highest NKTX revenue forecast at $14,113,750,800.
In 2029, NKTX is forecast to generate $9,284,730,964 in revenue, with the lowest revenue forecast at $7,847,245,445 and the highest revenue forecast at $11,617,028,283.